-
Media Release
Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
-
Media Release
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
-
Media Release
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
-
Media Release
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
-
Media Release
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
-
Media Release
Novartis showcases significant immunology advancements at ACR congress with new data in complex autoimmune diseases
-
Media Release
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
-
Media Release
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
-
Media Release
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
-
Media Release
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
-
Media Release
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Media Release
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US